Catalent and Roquette published an article in ONdrugDelivery exploring best practices for protecting moisture-sensitive inhalation products, including spray drying, powder collection, encapsulation, and blister packaging.
Public source
Publisher name
Public post
Moisture can have a significant impact on the performance and stability of inhalation powders, making environmental control essential throughout the manufacturing proces…
Company
Catalent
- Industry
- Pharmaceutical Manufacturing
- Location
- Tampa, US
- Company size
- 10,001+ employees
About Catalent
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
See moreLatest activity
Latest activity from Catalent
32 signals
People
Catalent welcomed President and CEO Alessandro Maselli to teams in Schorndorf, Eberbach, and Limoges across the European network.
Legal & Regulatory
Catalent supports Definium Therapeutics in receiving its second FDA Breakthrough Therapy designation for DT120 ODT for the treatment of major depressive disorder (MDD).
Operations & Supply
Catalent visited its Eberbach site and learned about Lean initiatives improving yield and reducing waste, investments in packaging operations, and site infrastructure.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Kindeva Drug Delivery
Kindeva Drug Delivery published an eBook exploring how formulation choices shape spray performance and regional deposition, device limitations as barriers for nose-to-brain delivery, reliability for rescue treatments, and regulatory ambiguity and particulate control.
Research & Knowledge
The Ritedose Corporation
The Ritedose Corporation published a new blog reviewing how pharmaceutical products are changing and how CDMOs and other manufacturers can succeed in the new environment.
Research & Knowledge
BIOAXXENT GmbH
BIOAXXENT GmbH published a recent review in Advanced Drug Delivery Reviews highlighting how biologic drug delivery is expanding beyond conventional injections, including advanced lipid and polymer formulations, sustained-release systems, site-specific delivery, and drug-device combinations.
Research & Knowledge
Colorcon®
Colorcon® published an article from Nutraceutical Business Review exploring key challenges, formulation, and packaging strategies to support probiotic product quality and shelf life.
Research & Knowledge
CARBOGEN AMCIS